Generic placeholder image

Current Drug Targets - CNS & Neurological Disorders


ISSN (Print): 1568-007X
ISSN (Online): 1568-007X

The Nrf2-ARE Signalling Pathway: Promising Drug Target to Combat Oxidative Stress in Neurodegenerative Disorders

Author(s): Freek L. van Muiswinkel and H. Bea Kuiperij

Volume 4 , Issue 3 , 2005

Page: [267 - 281] Pages: 15

DOI: 10.2174/1568007054038238

Price: $65


A large body of evidence indicates that oxidative stress is a salient pathological feature in many neurodegenerative diseases, including Amyotrophic lateral sclerosis, Alzheimers disease, and Parkinsons disease. In addition to signs of systemic oxidative stress, at the biochemical and neuropathological level, neuronal degeneration in these disorders has been shown to coincide with several markers of oxidative damage to lipids, nucleic acids, and proteins in affected brain regions. Neuroinflammatory processes, often associated with the induction of free radical generating enzymes and the accumulation of reactive astrocytes and microglial cells, are considered as a major source of oxidative stress. Given the pathogenic impact of oxidative stress and neuroinflammation, therapeutic strategies aimed to blunt these processes are considered an effective way to confer neuroprotection. Recently, the nuclear transcription factor Nrf2, that binds to the antioxidant response element (ARE) in gene promoters, has been reported to constitute a key regulatory factor in the coordinate induction of a battery of endogenous cytoprotective genes, including those encoding for both antioxidant- and anti-inflammatory proteins. In the present review, besides discussing recent evidence underscoring the thesis that the Nrf2-ARE signalling pathway is an attractive therapeutic target for neurodegenerative diseases, we advocate the view that chemopreventive agents might be suitable candidates to serve as lead compounds for the development of a new class of neuroprotective drugs.

Keywords: antioxidant response element, nrf, alzheimers disease, parkinsons disease, amyotrophic lateral sclerosis, monofunctional inducers, neuroprotection

Rights & Permissions Print Export Cite as
© 2022 Bentham Science Publishers | Privacy Policy